ArticleImmunology1993
The sheep analogue of human CD59: purification and characterization of its complement inhibitory activity.
Article in Immunology, 1993. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Characterization of the mouse analogues of CD59 using novel monoclonal antibodies: tissue distribution and functional comparison.Immunology · 2003Article
- Molecular basis for a link between complement and the vascular complications of diabetes.Proceedings of the National Academy of Sciences of the United States of America · 2000Article
- Production and functional characterization of a soluble recombinant form of mouse CD59.Immunology · 2000Article
- Characterization in vitro and in vivo of the pig analogue of human CD59 using new monoclonal antibodies.Immunology · 1998Article
- Expression of rat CD59: functional analysis confirms lack of species selectivity and reveals that glycosylation is not required for function.Immunology · 1997Article
- Mutational analysis of the active site and antibody epitopes of the complement-inhibitory glycoprotein, CD59.The Journal of experimental medicine · 1997Article
- GPI-anchored complement regulatory proteins in seminal plasma. An analysis of their physical condition and the mechanisms of their binding to exogenous cells.The Journal of clinical investigation · 1996Article
- Molecular cloning of the rat analogue of human CD59: structural comparison with human CD59 and identification of a putative active site.The Biochemical journal · 1994Article
- Membrane proteins that protect against complement lysis.Springer seminars in immunopathology · 1994Review
- Sequence-specific 1H-NMR assignments and folding topology of human CD59.Protein science : a publication of the Protein Society · 1993Article
- Expression of the glycosylphosphatidylinositol-linked complement-inhibiting protein CD59 antigen in insect cells using a baculovirus vector.The Biochemical journal · 1993Article
- Membrane defence against complement lysis: the structure and biological properties of CD59.Immunologic research · 1993Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
An inhibitor of the membrane attack complex of complement was isolated from the membranes of sheep erythrocytes. Fast protein liquid chromatography (FPLC) and affinity purification procedures for this sheep complement-inhibiting protein (SCIP) both yielded a pure protein with an apparent M(r) of 19,000 under reducing and non-reducing conditions. Incubation of the denatured protein with neuraminidase and Endo-F reduced the apparent M(r) to 18,000 and 15,000 respectively, while treatment with O-deglycosidase or phosphatidylinositol-specific phospholipase C (PIPLC) did not affect the apparent M(r). SCIP was detectable on erythrocytes and lymphocytes but not on platelets and could partially be removed by PIPLC treatment. Deglycosylation of the pure protein markedly reduced and PIPLC treatment abolished its activity. A monoclonal antibody (mAb) raised against sheep complement-inhibiting protein (SCIP) enhanced the susceptibility of sheep erythrocytes to lysis by homologous complement. SCIP inhibited complement after the stage of C5b-7 formation. Amino-terminal protein sequence was obtained and was shown to be similar to that of human CD59. All these features suggest that SCIP is the sheep equivalent of human CD59. Human CD59 has been reported to be species selective in that it inhibits complement from relatively few species. However, SCIP efficiently inhibited lysis of guinea-pig erythrocytes by complement from a wide range of species tested indicating that it is a potent and non-selective inhibitor of the membrane attack complex of complement (MAC).
Indexed as
Identifiers
7682985PMC1421828What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.